Affiliation:
1. FSBI “Zakusov Institute of Pharmacology”
Abstract
GIZh-290 is a new derivative of 4-phenylpyrrolidone, based on the structures of racetams that combine anticonvulsant and nootropic effects. The method of high-performance liquid chromatography with mass spectrometric detection was developed and validated for the quantitative determination of a new potential anticonvulsant compound GIZh-290 in rat blood plasma. For the extraction of the analyte, liquid-liquid extraction with diethyl ether was used. The method was validated based on its selectivity, linearity, accuracy, precision, and stability. The linearity of the method was confirmed by a high correlation coefficient of 0.999. The percent recovery of GIZh-290 from blood plasma was 79.2 %. The intra- and inter-batch accuracy were 19.32 and 12.14 %. It was found that blood plasma samples containing GIZh-290 can be stored at ambient temperature during the working day.
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference12 articles.
1. Zhmurenko LA, Litvinova SA, Mokrov GV, Kovalev IG, Voronina TA, Nerobkova LN, Gudasheva TA. Synthesis of 4-phenylpyrrolidone derivatives with anticonvulsant and nootropic activity. Pharmaceutical Chemistry Journal. 2019;53(5):20–27. (In Russ). DOI:10.30906/0023-1134-2019-53-5-20-27.
2. Kovalev IG. Search for compounds with anticonvulsant activity among new derivatives of 4-phenylpyrrolidone and coumarin and study of their neurochemical mechanisms of action. [dissertation] Moscow: 2017. (In Russ). Доступно по: https://www.academpharm.ru/images/upload/ru/1510/Dissertaciya_Kovalev_I.G.pdf.
3. Kovalev IG, Voronina TA, Litvinova SA, Zhmurenko LA, Mokrov G V. Comparison of anticonvulsant and mnemotropic properties of new derivatives of 4-phenylpyrrolidone, levetiracetam and piracetam. Russian Journal of Experimental and Clinical Pharmacology. 2017;80(6):13–18. (In Russ). DOI:10.30906/0869-2092-2017-80-6-13-18.
4. Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr. 2006;20(5):383-414. DOI: 10.1002/bmc.594
5. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev. 2003;22(3):195–214. DOI: 10.1002/mas.10050.